J&J to acquire eye disease-focused biotech firm Ollin Biosciences for up to
Article excerpt
by Sneha S K Johnson & Johnson JNJ.N announced on Monday that it has reached an agreement to acquire Texas-based biotech company Ollin Biosciences for up to 3.33 billion dollars, expanding its portfolio of treatments for eye diseases. Ollin’s experimental eye disease treatment, OLN324, will help J&J strengthen its presence in a field where its footprint remains limited, despite its major contact lens business. OLN324 is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two major causes of vision loss. According to J&J estimates, these two conditions together affect more than 40 million people worldwide. "Johnson & Johnson has built a strong reputation in ophthalmology through its surgical equipment and eye care products, primarily ACUVUE contact lenses, which makes this strategic alliance entirely logical," said Trung Huynh, an analyst at RBC Capital Markets. In a recent early-phase comparative study, the drug showed faster and greater improvements in eye structure, as well as superior visual gains in both diabetic macular edema (DME) and wet AMD, compared to Roche's ROPC.S Vabysmo, Ollin stated. The acquisition includes an upfront payment of 2.2 billion dollars and potential milestone payments linked to regulatory approvals and commercialization of up to 1.13 billion dollars, J&J specified. The transaction is expected to...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
Extracted from this sentence
J&J also announced that it would enter into a separate agreement with Blackstone Life Sciences for multi-year financing of 750 million dollars dedicated to the advanced development of OLN324, in exchange for certain payments and royalties.
